📰 What This Document Is 📣

This document is a Current Report (Form 8-K) that serves as Boston Scientific's official announcement of its financial performance for the first quarter of 2026. Because it is an 8-K, it is designed to immediately inform investors and the public about key operational and financial results as soon as they are finalized.

👉 This filing is crucial because it gives a snapshot of the company’s health, highlights its biggest wins in medical technology, and sets expectations for the rest of the year.

🏥 What Boston Scientific Does 🌎

Boston Scientific is a global medical technology leader with over 45 years of experience. In simple terms, the company designs and manufactures innovative devices and therapies that help diagnose and treat complex health issues.

👉 They make money by providing high-performance solutions for various complex conditions, including cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases. Their mission is to advance science to improve patients' lives worldwide.

📈 Q1 2026 Financial Performance 💰

Boston Scientific reported solid financial results for the first quarter of 2026. The company generated net sales of $5.203 billion.

• Sales Growth: Net sales increased by 11.6 percent on a reported basis, compared to the prior year period. Operationally, the growth was 9.4 percent (or 11.2% on an operational and organic basis).
  • Why it matters: The strong growth signals that demand for their medical devices remains high despite a challenging global economic environment.
• Profitability: The company reported GAAP net income attributable to common stockholders of $1.341 billion.
  • Why it matters: This is a significant increase compared to the $674 million reported in the first quarter of 2025, showing improved bottom-line performance.
• Earnings Per Share (EPS): Basic GAAP EPS was $0.90 per share. On a non-GAAP basis, they reported adjusted EPS of $0.80 per share, slightly up from the $0.75 reported in Q1 2025.

🎯 Management’s Strategic Commentary 🗣️

CEO Mike Mahoney provided commentary reinforcing the company’s strategic direction and overall health. He stated, “Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter.”

👉 The CEO affirmed that the company remains focused on executing its long-term strategy and advancing its "differentiated pipeline to drive meaningful impact."

📊 Segment and Regional Growth Highlights 🌍

The company broke down its strong revenue growth across specific business areas and geographical markets.

Business Segment Performance

• Cardiovascular: This segment was the top revenue driver, achieving a reported net sales growth of 13.5 percent and an operational and organic growth of 11.2 percent.
  • Why it matters: The high growth here suggests successful penetration into crucial heart health markets, which is a core part of their business.
• MedSurg: Reported a net sales increase of 7.8 percent on a reported basis.
• Other Segments: The company also reports performance data for Endoscopy (9.4% reported growth) and Urology (2.1% reported growth).

Regional Performance

• Asia-Pacific (APAC): Was the strongest region, posting a reported growth of 14.7 percent and an operational growth of 12.0 percent.
• Latin America and Canada (LACA): Showed exceptional growth, achieving a reported net sales increase of 19.0 percent, with operational growth at 12.0 percent.
• United States (U.S.): Posted a reported growth of 10.9 percent and an operational growth of 10.9 percent.

🧪 Clinical and Product Development Wins 🥇

This quarter was marked by several significant clinical announcements, showcasing the success of their R&D pipeline. These wins help cement their market leadership in specific treatment areas.

• Watchman FLX™ (Atrial Fibrillation): The CHAMPION-AF study presented positive outcomes, demonstrating that the WATCHMAN FLX device is a first-line option that achieved superior bleeding risk reduction compared to oral anticoagulants, while maintaining similar efficacy.
• EKOS™ (Acute PE): The HI-PEITHO trial showed that using the EKOS system plus anticoagulation was superior for treating acute pulmonary embolism (PE) compared to using anticoagulation alone.
• FARAPULSE™ (Advanced Ablation): The ADVENT Long-Term Outcomes trial published positive data, suggesting that using FARAPULSE™ Pulsed Field Ablation (PFA) provides greater long-term AF treatment success, fewer hospital interventions, and lower repeat ablation rates at four years compared to thermal ablation.
• Urology (Asurys™): The company received U.S. FDA 510(k) clearance for the Asurys™ Fluid Management System, which helps manage real-time irrigation during complex endoscopic procedures.
• Nalu Neurostimulation System: Outcomes from the 24-month COMFORT clinical trial demonstrated durable and statistically significant pain relief for chronic pain patients.
• China Market: The company received National Medical Products Association approval in China for the OPAL HDx™ Mapping System.

🔮 Future Guidance and Strategy 🚀

The company provided clear guidance for the second quarter and the full fiscal year, setting expectations for continued strong performance.

• Full Year 2026 Guidance (vs. prior year):
  • Reported net sales growth is estimated to be between 7.0 to 8.5 percent.
  • The organic net sales growth is estimated to be between 6.5 to 8.0 percent.
• Second Quarter 2026 Guidance (vs. prior year):
  • Reported net sales growth is estimated to be between 5.5 to 7.5 percent.
  • The organic net sales growth is estimated to be between 5.0 to 7.0 percent.
• Q2 2026 Adjusted EPS Guidance: The company estimates adjusted EPS to be between $0.82 to $0.84 per share.

🤝 Corporate and Operational Updates 🏢

The filing detailed several key corporate moves that expand the company's operational capacity and governance.

• Acquisition Completion: Boston Scientific completed the acquisition of Valencia Technologies Corporation, which specializes in the eCoin® System, an implantable tibial nerve stimulation device for treating urge urinary incontinence.
• Board Refresh: The board of directors added two new members: Cathy Smith, CFO of Starbucks, and Christophe Weber, President and CEO of Takeda Pharmaceutical.
  • Why it matters: Adding executives from major corporations like Starbucks and Takeda adds financial and pharmaceutical expertise to the board.

📘 Financial Statement Deep Dive 📊

The filing provided detailed tables comparing 2026 results to 2025 results, showing both GAAP and non-GAAP measures for investors.

• Non-GAAP Adjustments: The company provides extensive documentation on its non-GAAP adjustments. These include excluding items like amortization expense, restructuring charges, and deferred tax effects, which management believes gives a clearer picture of the core operational performance.
• Key Comparison: In the non-GAAP reconciliation, Q1 2026 showed an adjusted net income of $1,347 million, a significant increase from the $1,121 million reported in Q1 2025.

📞 Where to Find More Information ℹ️

For follow-up discussion and detailed information, the company provided clear contacts for investors and media.

• Conference Call: Management will discuss these results with analysts on a conference call at 8:00 a.m. ET. Webcasting details are available at investors.bostonscientific.com.
• Media Relations: Chanel Hastings, 508-382-0288 (office) / [email protected]
• Investor Relations: Lauren Tengler, 508-683-4479 (office) / [email protected]

🧠 The Analogy

Think of Boston Scientific like a highly specialized, continuously upgrading Swiss watchmaker. Instead of just telling time, they are developing miniature, precision tools—the medical devices—that solve increasingly complex health problems, from heart arrhythmias to chronic pain. Each positive clinical trial is like gaining a new, certified caliber of movement for their product lineup, making their overall "watch" (the patient care portfolio) more reliable and advanced over time.

🧩 Final Takeaway

Boston Scientific reported strong Q1 2026 growth, fueled by outstanding performance in its Cardiovascular and APAC regions. The company’s commitment to a differentiated pipeline, proven by multiple successful clinical trial readouts, validates its position as a global leader in medical innovation.